Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
February 2, 2018 Off

Cardinal Health sells its China-based subsidiary to Shanghai Pharmaceuticals for $1.2 billion

By Dino Mustafić

Cardinal Health has disposed a business unit for $1.2 billion – its Cardinal Health China – to Shanghai Pharmaceuticals Holding.

February 2, 2018 Off

Adler closes offering $250M of 2.50% Convertible Senior Notes Due 2025

By Dino Mustafić

A migraine treatment focused biopharmaceutical specialist, Alder BioPharmaceuticals,  has closed on Thursday previously announced underwritten offering of $250 million aggregate…

Mylan launches Efavirenz in USA, first generic version of BMS’s HIV type 1 treatment Sustiva
February 1, 2018 Off

Mylan launches Efavirenz in USA, first generic version of BMS’s HIV type 1 treatment Sustiva

By Dino Mustafić

Mylan is launching Efavirenz Tablets USP, 600 mg, in the USA, the first generic version of Bristol-Myers Squibb’s Sustiva, which…

February 1, 2018 Off

Faron to kick off developing Clevegen for cancer, as it got patent for its antibodies from European Patent Office

By Dino Mustafić

Faron Pharmaceuticals has gotten a patent from European Patent office, for Clever-1 antibodies, the mechanism for the Clevegen, the treatment…

Novo Nordisk’s study shows reductions in blood sugar and weight compared with dulaglutide for type 2 diabetes, sales in diabetes, obesity increased
February 1, 2018 Off

Novo Nordisk’s study shows reductions in blood sugar and weight compared with dulaglutide for type 2 diabetes, sales in diabetes, obesity increased

By Dino Mustafić

Novo Nordisk has published the results for semaglutide from a study aiming to test the treatment for type 2 diabetes.

STADA announces the new CEO, to step in in September
February 1, 2018 Off

STADA announces the new CEO, to step in in September

By Dino Mustafić

Stada has announced the new name to succeed the current CEO Claudio Albrecht in September this year.

Vertex takes next step in testing medicine to treat the underlying cause of  cystic fibrosis
February 1, 2018 Off

Vertex takes next step in testing medicine to treat the underlying cause of cystic fibrosis

By Dino Mustafić

Vertex Pharmaceuticals will move its cystic fibrosis treatment VX-659 and VX-445 into Phase 3, the company said Wednesday, after the initial…

February 1, 2018 Off

Nordic Nanovector names new leader for communication with investors and media

By Dino Mustafić

Nordic Nanovector ASA has appointed Malene Brondberg as Vice President, Investor Relations and Corporate Communications. Malene will lead the engagement and…

Zogenix sends last patient into second Phase 3 trial for its supporting treatment for Dravet syndrome young patients
January 31, 2018 Off

Zogenix sends last patient into second Phase 3 trial for its supporting treatment for Dravet syndrome young patients

By Dino Mustafić

Zogenix, a NASDAQ-listed pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, has randomized the last…

Alkermes waits FDA’s green light for its investigational depressive disorder treatment
January 31, 2018 Off

Alkermes waits FDA’s green light for its investigational depressive disorder treatment

By Dino Mustafić

Alkermes will attempt to get new approval from the USFDA for its investigational drug for treating major depressive disorder (MDD).

Posts pagination

Previous 1 … 3,409 3,410 3,411 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine